MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$29,455,454
EPS
-$0.7
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
-
-
2,595,486*
-
General and administrative
-
-
2,020,301.25*
-
Total operating expenses
-
-
4,615,787.25
-
Research and development
1,736,013
2,338,345
-
2,386,244
Loss from operations
-
-
-4,615,787.25*
-
General and administrative
2,110,453
2,507,383
-
1,976,335
Other income (expenses)
-
-
60.5*
-
Total operating expenses
3,846,466
4,845,728
-
4,362,579
Stock-based inducement expense
-
-
215,887.5*
-
Loss from operations
-3,846,466
-4,845,728
-
-4,362,579
Write off of deferred offering costs
-
-
151,354.75*
-
Other income
-
173
-
248
(loss) gain on foreign currency
-52
-
-
-
Interest income (expense), net
-
-
2,903.5*
-
Derivative expense
3,103,533
896,722
-
-
Total other income (expenses), net
-
-
-364,278.25*
-
Change in fair value of earnout liability
-
-19,500
-
-
Change in fair value of preferred stock liabilities
-6,610,240
-
-
-
Net loss
-
-
-4,980,065.5*
-
Write off of deferred offering costs
-
-
-
500,000
Interest income
1,025
3,149
-
-
Deemed dividend on series a, b and c preferred stock
-
-
7,122,311.25*
-
Interest income (expense), net
-
-
-
5,936
Interest expense
690,044
166,286
-
-
Deemed dividend on series d preferred stock
-
-
19,176,530.5*
-
Total other income (expenses), net
2,817,636
-1,040,186
-
-493,816
Deemed dividend on series e preferred stock
-
-
1,790,827*
-
Net loss
-1,028,830
-5,885,914
-
-4,856,395
Deemed dividend related to series c common warrants
-
-
21,020.75*
-
Deemed dividend on series d preferred stock
-
-
-
6,649,828
Deemed dividend on series a, b, c, d and e preferred stock
28,426,624
-
-
-
Net loss attributable to common shareholders
-29,455,454
-5,885,914
-33,090,755
-11,506,223
Basic EPS
-0.7
-0.2
-7.823
-9.1
Diluted EPS
-0.7
-0.2
-7.823
-9.1
Basic Average Shares
42,175,020
28,755,073
4,229,849*
1,264,884
Diluted Average Shares
42,175,020
28,755,073
4,229,849*
1,264,884
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$29,455,454
(2.20%↑ Y/Y)
Change in fair value of
preferred stock...
-$6,610,240
Interest income
$1,025
Deemed dividend on
series a, b, c, d and e...
$28,426,624
Net loss
-$1,028,830
(81.01%↑ Y/Y)
Total other income
(expenses), net
$2,817,636
(506.28%↑ Y/Y)
Derivative expense
$3,103,533
Interest expense
$690,044
(loss) gain on foreign
currency
-$52
Loss from operations
-$3,846,466
(18.57%↑ Y/Y)
Total operating
expenses
$3,846,466
(-18.57%↓ Y/Y)
General and
administrative
$2,110,453
(7.14%↑ Y/Y)
Research and development
$1,736,013
(-36.96%↓ Y/Y)
Buy us a coffee
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)